CME: Advanced Prostate Cancer (aPC): Therapeutic Updates, Best Practices, and Emerging Treatments
Cost: FreeView Offer chevron_right
Prostate cancer is the most common form of malignancy among men in the United States.There are over 164,600 new cases and over 29,000 deaths from PC in the U.S. annually. Probable risk factors include age 65 and older, African American ancestry, family history, and mutations in the BRCA1, -2, MSH2, and HOXB13 genes, with possible risk factors including occupational exposure to cadmium, dietary factors, and higher concentrations of serum testosterone. About 95% of cases are adenocarcinoma, with neuroendocrine tumors, sarcomas, and transitional cell carcinomas comprising the balance of tumor types. Symptoms of advanced prostate cancer (aPC) include back pain, cord compression, lower extremity edema, pathologic fractures, anemia, and weight loss.
By the end of the session the participant will be able to:
- Describe the pathophysiology of aPC
- Identify the present treatment options currently available for management of aPC
- Evaluate the safety and effectiveness of certain treatment options in specific patient populations and apply this knowledge to patient cases using evidence-based medicine
- Describe complications associated with prostate cancer and its treatment (bone, cardiovascular, and endocrinologic risk factors) and develop risk mitigation and optimization strategies
The following HCPs: oncologists and urologists; physician assistants, nurse practitioners, nurses, and pharmacists specializing in oncology; and any other HCPs with an interest in or who may clinically encounter patients with aPC.